Should You Buy Bioatla Inc (BCAB) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast BCAB stock price to rise
2 Analyst Rating
Wall Street analysts forecast BCAB stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.050
Low
4
Averages
7
High
10
Current: 4.050
Low
4
Averages
7
High
10
Citizens JMP
Reni Benjamin
Outperform -> Market Perform
downgrade
$NULL
AI Analysis
2025-08-13
Reason
Citizens JMP
Reni Benjamin
Price Target
$NULL
AI Analysis
2025-08-13
downgrade
Outperform -> Market Perform
Reason
Citizens JMP analyst Reni Benjamin downgraded BioAtla to Market Perform from Outperform without a price target following the Q2 report. The firm views the shares as fairly valued given expecatatations for no revenue or earnings in the near future. BioAtla is facing an evolving landscape and uncertainty regarding a potential partnership, the analyst tells investors in a research note. With a partnership, Citizens views the company's current cash position as insufficient to sustain operations.
